An Ngo-Huang1, Nathan H Parker2,3, Xuemei Wang4, Maria Q B Petzel2,5, David Fogelman6, Keri L Schadler7, Eduardo Bruera8, Jason B Fleming2, Jeffrey E Lee2, Matthew H G Katz2. 1. Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1414, Houston, TX, 77030, USA. ango2@mdanderson.org. 2. Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Health and Human Performance, University of Houston, Houston, TX, USA. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Clinical Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8. Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1414, Houston, TX, 77030, USA.
Abstract
PURPOSE: Exercise concurrent with neoadjuvant chemotherapy and/or chemoradiation for pancreatic adenocarcinoma (PDAC) may mitigate the decline in function that may occur as a result of the disease or its treatment in the preoperative period. The primary objective of this single-arm prospective trial was to determine adherence to a home-based exercise program administered during preoperative therapy. METHODS: Twenty patients from a quaternary cancer center with potentially resectable PDAC were enrolled. Patients were prescribed a minimum of 120 min of moderate-intensity exercise weekly: at least 60 min of aerobic exercise and 60 min of resistance exercise. Self-reported exercise was recorded in daily logs. Functional and survey measures were collected upon enrollment, following preoperative therapy, and 1 month after surgery. RESULTS: Fifteen out of 20 patients participated in the program. They reported a mean (standard deviation (SD)) of 98.6 (69.8) min of aerobic exercise weekly and 57.4 (36.0) min of strengthening exercise weekly over a median of 17 weeks (range, 5-35 weeks) of preoperative therapy, for a mean (SD) of 156.0 (64.5) min of total exercise weekly. Eighty percent reported a mean of least 120 min of total exercise weekly during preoperative therapy. Patients with low baseline physical activity based on the International Physical Activity Questionnaire significantly increased their preoperative physical activity (p = .01). There were no adverse events associated with the exercise program. CONCLUSIONS: Patients with PDAC will participate in a home-based exercise program of aerobic and strengthening exercise and will increase physical activity, concurrent with preoperative chemotherapy and/or chemoradiation.
PURPOSE: Exercise concurrent with neoadjuvant chemotherapy and/or chemoradiation for pancreatic adenocarcinoma (PDAC) may mitigate the decline in function that may occur as a result of the disease or its treatment in the preoperative period. The primary objective of this single-arm prospective trial was to determine adherence to a home-based exercise program administered during preoperative therapy. METHODS: Twenty patients from a quaternary cancer center with potentially resectable PDAC were enrolled. Patients were prescribed a minimum of 120 min of moderate-intensity exercise weekly: at least 60 min of aerobic exercise and 60 min of resistance exercise. Self-reported exercise was recorded in daily logs. Functional and survey measures were collected upon enrollment, following preoperative therapy, and 1 month after surgery. RESULTS: Fifteen out of 20 patients participated in the program. They reported a mean (standard deviation (SD)) of 98.6 (69.8) min of aerobic exercise weekly and 57.4 (36.0) min of strengthening exercise weekly over a median of 17 weeks (range, 5-35 weeks) of preoperative therapy, for a mean (SD) of 156.0 (64.5) min of total exercise weekly. Eighty percent reported a mean of least 120 min of total exercise weekly during preoperative therapy. Patients with low baseline physical activity based on the International Physical Activity Questionnaire significantly increased their preoperative physical activity (p = .01). There were no adverse events associated with the exercise program. CONCLUSIONS:Patients with PDAC will participate in a home-based exercise program of aerobic and strengthening exercise and will increase physical activity, concurrent with preoperative chemotherapy and/or chemoradiation.
Entities:
Keywords:
Cancer rehabilitation; Pancreatic cancer; Prehabilitation; Preoperative exercise
Authors: J J Dronkers; H Lamberts; I M M D Reutelingsperger; R H Naber; C M Dronkers-Landman; A Veldman; N L U van Meeteren Journal: Clin Rehabil Date: 2010-06-08 Impact factor: 3.477
Authors: Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: S Jack; M A West; D Raw; S Marwood; G Ambler; T M Cope; M Shrotri; R P Sturgess; P M A Calverley; C H Ottensmeier; M P W Grocott Journal: Eur J Surg Oncol Date: 2014-03-27 Impact factor: 4.424
Authors: Karin Valkenet; Ingrid G L van de Port; Jaap J Dronkers; Wouter R de Vries; Eline Lindeman; Frank J G Backx Journal: Clin Rehabil Date: 2010-11-08 Impact factor: 3.477
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Sue-Anne McLachlan; Richard J Fisher; John Zalcberg; Michael Solomon; Bryan Burmeister; David Goldstein; Trevor Leong; Stephen P Ackland; Joseph McKendrick; Bev McClure; John Mackay; Samuel Y Ngan Journal: Eur J Cancer Date: 2016-01-07 Impact factor: 9.162
Authors: Nathan H Parker; An Ngo-Huang; Rebecca E Lee; Daniel P O'Connor; Karen M Basen-Engquist; Maria Q B Petzel; Xuemei Wang; Lianchun Xiao; David R Fogelman; Keri L Schadler; Richard J Simpson; Jason B Fleming; Jeffrey E Lee; Gauri R Varadhachary; Sunil K Sahai; Matthew H G Katz Journal: Support Care Cancer Date: 2018-10-17 Impact factor: 3.603
Authors: J Chmelo; A W Phillips; A Greystoke; S J Charman; L Avery; K Hallsworth; J Welford; R C F Sinclair Journal: Pilot Feasibility Stud Date: 2020-04-23
Authors: An Ngo-Huang; Holly M Holmes; Jude K A des Bordes; Nathan H Parker; David Fogelman; Maria Q B Petzel; Juhee Song; Eduardo Bruera; Matthew H G Katz Journal: Cancer Med Date: 2019-04-29 Impact factor: 4.452
Authors: Claudia Alvarez Florez Bedoya; Ana Carolina Ferreira Cardoso; Nathan Parker; An Ngo-Huang; Maria Q Petzel; Michael P Kim; David Fogelman; Salvador Gabriel Romero; Huamin Wang; Minjeong Park; Matthew H G Katz; Keri L Schadler Journal: Sci Rep Date: 2019-09-27 Impact factor: 4.379